Tag: Current

Dupilumab (Dupixent) and tralokinumab (Adbry) are immunotherapy drugs approved to treat moderate to severe eczema. Other potential treatments are undergoing clinical trials. Immunotherapy is a treatment option for moderate or severe atopic dermatitis (eczema) that doesn’t respond to other treatments. This class of drugs uses your body’s immune system to alter reactions that contribute to […]